OBJECTIVE： To evaluate the clinical efficacy and economics of vasoactive drugs for esophageal and gastric varices bleeding （EGVB） causes by cirrhosis. METHODS： By evidence-based medicine method， domestic pharmacoeconomic research literatures were retrieved and screened， Meta-analysis of included literatures were conducted by RevMan 5.2 software； clinical efficacies of different vasoactive drugs for EGVB caused by cirrhosis were evaluated and pharmacoeconomic analysis was done to evaluate the economics of different plans. RESULTS： A total of 10 literatures were included. Meta-analysis of hemostatic efficiency in 4 studies （130 cases of octreotide group， 135 cases of somatostatin group） showed that hemostatic efficiency of 2 groups were similar to each other [RR＝0.89， 95％CI （0.80， 1.00），P＝0.06]， but average hemostatic time of octreotide group was longer than that of somatostatin group [SMD＝0.32， 95％CI （0.06，0.58），P＝0.01]； the cost of octreotide group was lower than that of somatostatin group （3 889 yuan vs. 4 814 yuan）. Meta-analysis of hemostatic efficiency in 5 studies showed that hemostatic efficiency of octreotide group （146 cases） was better than that of pituitrin group （125 cases） [RR＝1.42，95％CI（1.05，1.91），P＝0.02]； cost-effective ratio of 2 groups were 23.66 and 3.13. Meta-analysis of hemostatic efficiency in 3 studies showed that hemostatic efficiency of 2 groups  （94 cases in each group） were similar to each other [RR＝1.06， 95％CI （0.87， 1.28），P＝0.57]， but the cost of the latter was lower than that of the former （744 yuan vs. 2 761 yuan）. CONCLUSIONS： From the aspect of hemostatic efficiency of octreotide， somatostatin and pituitrin for EGVB caused by cirrhosis， octreotide is better than pituitrin， and other difference is not significant. From the aspect of economics， pituitrin is the most economical， and octreotide is lower than somatostatin. Individual therapy plan should be selected according to disease condition， economical situation and ADR.